Profile data is unavailable for this security.
About the company
RPG Life Sciences Limited is an India-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas, including nephrology, oncology, rheumatology, cardiology, respiratory, nutritional, gastroenterology, and diabetology, among others. The International Formulations business operates in the generics and branded generics space across regulated and emerging markets. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Nicorandil, Quinfamide, Nicorandil, Haloperidol, Risperidone, Tolvaptan, Spironolactone, Sertraline, Lamotrigine, and others.
- Revenue in INR (TTM)6.00bn
- Net income in INR923.20m
- Incorporated2007
- Employees1.27k
- LocationRPG Life Sciences LimitedRPG House463, Dr. Annie Besant Road, WorliMUMBAI 400030IndiaIND
- Phone+91 2 224981650
- Fax+91 2 224970127
- Websitehttps://www.rpglifesciences.com/website/index.php
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Themis Medicare Ltd | 4.08bn | 500.16m | 23.77bn | 1.54k | 47.57 | -- | 38.57 | 5.83 | 5.43 | 5.43 | 44.31 | -- | -- | -- | -- | 2,648,322.00 | -- | 11.12 | -- | 16.46 | 63.51 | 60.32 | 12.26 | 14.96 | -- | -- | -- | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| IOL Chemicals and Pharmaceuticals Ltd. | 20.72bn | 1.19bn | 28.29bn | 2.78k | 23.86 | -- | 15.30 | 1.37 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| Dishman Carbogen Amcis Ltd | 24.16bn | -2.48bn | 28.62bn | 1.13k | -- | -- | 165.73 | 1.18 | -15.81 | -15.81 | 154.06 | -- | -- | -- | -- | 21,344,260.00 | -- | -0.3986 | -- | -0.4888 | 79.30 | 73.83 | -10.27 | -1.54 | -- | -0.7216 | -- | -- | 8.41 | 4.91 | -414.93 | -- | -0.3175 | -- |
| SMS Pharmaceuticals Ltd | 7.38bn | 569.64m | 30.22bn | 1.20k | 52.89 | -- | 33.96 | 4.09 | 6.75 | 6.75 | 87.48 | -- | -- | -- | -- | 6,168,549.00 | -- | 5.43 | -- | 7.33 | 30.12 | 33.30 | 7.69 | 7.87 | -- | 4.21 | -- | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Solara Active Pharma Sciences Ltd | 13.00bn | -5.61bn | 31.68bn | 2.16k | -- | -- | -- | 2.44 | -143.75 | -143.75 | 334.17 | -- | -- | -- | -- | 6,030,149.00 | -- | -2.44 | -- | -3.84 | 37.34 | 41.16 | -43.17 | -4.49 | -- | -1.57 | -- | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Indoco Remedies Ltd | 18.22bn | 766.90m | 34.06bn | 5.93k | 44.80 | -- | 19.56 | 1.87 | 8.25 | 8.25 | 178.33 | -- | -- | -- | -- | 3,072,462.00 | -- | 6.88 | -- | 9.85 | 68.61 | 65.59 | 4.10 | 6.93 | -- | 2.95 | -- | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 34.42bn | 1.23k | -- | 108.86 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| RPG Life Sciences Limited | 6.00bn | 923.20m | 34.94bn | 1.27k | 37.84 | -- | 31.63 | 5.83 | 55.82 | 55.82 | 362.60 | -- | -- | -- | -- | 4,721,969.00 | -- | 16.07 | -- | 21.77 | 68.42 | 62.99 | 15.39 | 11.99 | -- | 220.43 | -- | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Gufic BioSciences Ltd | 8.14bn | 863.69m | 40.16bn | 1.45k | 46.04 | -- | 38.82 | 4.93 | 8.70 | 8.70 | 81.95 | -- | -- | -- | -- | 5,624,707.00 | -- | 11.46 | -- | 19.21 | 52.39 | 45.79 | 10.60 | 10.46 | -- | 8.09 | -- | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| SeQuent Scientific Ltd | 14.27bn | 54.87m | 43.00bn | 1.20k | 807.64 | -- | 55.35 | 3.01 | 0.2137 | 0.2137 | 57.18 | -- | -- | -- | -- | 11,939,190.00 | -- | 1.09 | -- | 1.76 | 45.38 | 41.97 | 0.9902 | 1.18 | -- | 0.9009 | -- | 35.06 | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
| Innova Captab Ltd | 11.42bn | 1.06bn | 44.28bn | -- | 32.66 | -- | 35.64 | 3.88 | 23.69 | 23.69 | 236.62 | -- | -- | -- | -- | -- | -- | 10.82 | -- | 18.38 | 33.38 | 25.18 | 9.30 | 8.04 | -- | 8.89 | -- | -- | 16.72 | 24.90 | 38.84 | 36.55 | 104.14 | -- |
| Unichem Laboratories Ltd | 17.28bn | -605.50m | 45.11bn | 3.19k | -- | -- | 86.35 | 2.61 | -8.59 | -8.59 | 245.15 | -- | -- | -- | -- | 5,410,587.00 | -- | -1.67 | -- | -2.03 | 62.00 | 56.18 | -3.50 | -3.99 | -- | 0.1401 | -- | -- | 26.94 | 7.64 | 65.15 | -- | -35.00 | -- |
| Morepen Laboratories Ltd | 17.45bn | 1.18bn | 45.91bn | 1.62k | 36.26 | -- | 30.68 | 2.63 | 2.31 | 2.31 | 34.26 | -- | -- | -- | -- | 10,749,300.00 | -- | 7.90 | -- | 13.34 | 37.86 | 33.34 | 6.77 | 5.49 | -- | 33.34 | -- | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Hikal Ltd | 18.03bn | 677.82m | 46.42bn | 2.06k | 68.52 | -- | 24.50 | 2.57 | 5.49 | 5.49 | 145.97 | -- | -- | -- | -- | 8,749,879.00 | -- | 5.07 | -- | 7.51 | 53.06 | 46.78 | 3.76 | 5.86 | -- | 2.45 | -- | 12.19 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
Data as of Sep 20 2024. Currency figures normalised to RPG Life Sciences Limited's reporting currency: Indian Rupee INR
2.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Aug 2024 | 261.81k | 1.58% |
| quant Money Managers Ltd.as of 30 Aug 2024 | 38.61k | 0.23% |
| WhiteOak Capital Asset Management Ltd.as of 31 Aug 2024 | 9.69k | 0.06% |
| American Century Investment Management, Inc.as of 05 Sep 2024 | 8.85k | 0.05% |
| Acadian Asset Management LLCas of 30 Sep 2023 | 7.97k | 0.05% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 6.40k | 0.04% |
| State Board of Administration of Florida Retirement Systemas of 30 Jun 2023 | 2.05k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Aug 2024 | 1.38k | 0.01% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 223.00 | 0.00% |
| DFA Australia Ltd.as of 31 Jul 2024 | 11.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
